Your browser doesn't support javascript.
loading
COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational variance
Michiel Niesen; Praveen Anand; Eli Silvert; Rohit Suratekar; Colin Pawlowski; Pritha Ghosh; Patrick Lenehan; Travis Hughes; David Zemmour; John C OHoro; Joseph D Yao; Bobbi S Pritt; Andrew Norgan; Ryan T Hurt; Andrew D Badley; AJ Venkatakrishnan; Venky Soundararajan.
Afiliação
  • Michiel Niesen; nference
  • Praveen Anand; nference Labs
  • Eli Silvert; nference
  • Rohit Suratekar; nference Labs
  • Colin Pawlowski; nference
  • Pritha Ghosh; nference Labs
  • Patrick Lenehan; nference
  • Travis Hughes; nference
  • David Zemmour; nference
  • John C OHoro; Mayo Clinic
  • Joseph D Yao; Mayo Clinic
  • Bobbi S Pritt; Mayo Clinic
  • Andrew Norgan; Mayo Clinic
  • Ryan T Hurt; Mayo Clinic
  • Andrew D Badley; Mayo Clinic
  • AJ Venkatakrishnan; nference
  • Venky Soundararajan; nference
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21259833
ABSTRACT
Variants of SARS-CoV-2 are evolving under a combination of immune selective pressure in infected hosts and natural genetic drift, raising a global alarm regarding the durability of COVID-19 vaccines. Here, we conducted longitudinal analysis over 1.8 million SARS-CoV-2 genomes from 183 countries or territories to capture vaccination-associated viral evolutionary patterns. To augment this macroscale analysis, we performed viral genome sequencing in 23 vaccine breakthrough COVID-19 patients and 30 unvaccinated COVID-19 patients for whom we also conducted machine-augmented curation of the electronic health records (EHRs). Strikingly, we find the diversity of the SARS-CoV-2 lineages is declining at the country-level with increased rate of mass vaccination (n = 25 countries, mean correlation coefficient = -0.72, S.D. = 0.20). Given that the COVID-19 vaccines leverage B-cell and T-cell epitopes, analysis of mutation rates shows neutralizing B-cell epitopes to be particularly more mutated than comparable amino acid clusters (4.3-fold, p < 0.001). Prospective validation of these macroscale evolutionary patterns using clinically annotated SARS-CoV-2 whole genome sequences confirms that vaccine breakthrough patients indeed harbor viruses with significantly lower diversity in known B cell epitopes compared to unvaccinated COVID-19 patients (2.3-fold, 95% C.I. 1.4-3.7). Incidentally, in these study cohorts, vaccinated breakthrough patients also displayed fewer COVID-associated complications and pre-existing conditions relative to unvaccinated COVID-19 patients. This study presents the first known evidence that COVID-19 vaccines are fundamentally restricting the evolutionary and antigenic escape pathways accessible to SARS-CoV-2. The societal benefit of mass vaccination may consequently go far beyond the widely reported mitigation of SARS-CoV-2 infection risk and amelioration of community transmission, to include stemming of rampant viral evolution.
Licença
cc_by
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...